Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway. (Q55042835)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ly Quoc Trung

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Dao T An

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Nguyen Hoang Viet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kazuya Shimoda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Shinji Nakao

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

16 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

Molecular Nutrition and Food Research

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

2143-2154

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

The role of Janus kinases in haemopoiesis and haematological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Molecular insights into regulation of JAK2 in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Bioproduction of resveratrol and stilbene derivatives by plant cells and microorganisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Resveratrol--pills to replace a healthy diet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Resveratrol attenuates lipopolysaccharide-induced acute kidney injury by suppressing inflammation driven by macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Resveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Resveratrol addiction: to die or not to die.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Clinical trials of resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Resveratrol bioavailability and toxicity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Resveratrol: a natural polyphenol with multiple chemopreventive properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Drug combination studies and their synergy quantification using the Chou-Talalay method

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Ataxia-telangiectasia mutated kinase-mediated upregulation of NKG2D ligands on leukemia cells by resveratrol results in enhanced natural killer cell susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

3-O-methylthespesilactam, a new small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

ERK1/2 inhibition enhances apoptosis induced by JAK2 silencing in human gastric cancer SGC7901 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Activated Jak2 with the V617F point mutation promotes G1/S phase transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Resveratrol in human cancer chemoprevention--choosing the 'right' dose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Resveratrol nanoformulations: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

Enhancing the bioavailability of resveratrol by combining it with piperine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201500166

21 January 2018

Identifiers

DOI

10.1002/MNFR.201500166

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26375873%20AND%20SRC:MED&resulttype=core&format=json